NEW YORK (GenomeWeb) SkylineDx, a Dutch molecular diagnostics company, has developed a new algorithm that can be used to predict the optimal treatment for patients with multiple myeloma.

The new computational tool, called TOPSPIN, complements the company's MMprofiler test, which stratifies multiple myeloma patients based on their microarray gene expression profile.

Using that information, clinicians can decide on a course of treatment according to their patient's genetic subtype.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.